ALLO Logo

Allogene Therapeutics, Inc. (ALLO) 

NASDAQ
Market Cap
$398.38M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
76 of 963
Rank in Industry
56 of 552

Largest Insider Buys in Sector

ALLO Stock Price History Chart

ALLO Stock Performance

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Insider Activity of Allogene Therapeutics, Inc.

Over the last 12 months, insiders at Allogene Therapeutics, Inc. have bought $5M and sold $158,820 worth of Allogene Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Allogene Therapeutics, Inc. have bought $6.97M and sold $28.82M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Belldegrun Arie (director) — $5M. Parker Geoffrey M. (CHIEF FINANCIAL OFFICER) — $2,049.

The last purchase of 1,724,137 shares for transaction amount of $5M was made by Belldegrun Arie (director) on 2024‑05‑16.

List of Insider Buy and Sell Transactions, Allogene Therapeutics, Inc.

2024-12-09Saledirector
9,136
0.0042%
$2.18$19,916-5.73%
2024-12-05Saledirector
9,221
0.0044%
$2.16$19,917+2.34%
2024-06-18Saledirector
18,641
0.008%
$2.28$42,488+18.39%
2024-05-30Saledirector
11,200
0.0051%
$2.34$26,181+6.10%
2024-05-16Purchasedirector
1.72M
0.9747%
$2.90$5M-13.50%
2024-01-30PurchaseCHIEF FINANCIAL OFFICER
190
0.0001%
$3.60$683-21.93%
2023-12-18Saledirector
18,640
0.0103%
$2.70$50,317-0.69%
2023-08-07Saledirector
10,000
0.0069%
$4.29$42,855-25.59%
2023-02-13SaleGeneral Counsel
3,000
0.002%
$6.85$20,550-40.59%
2023-01-17SaleGeneral Counsel
3,000
0.0021%
$7.04$21,120-31.37%
2022-12-15SaleGeneral Counsel
5,602
0.0041%
$7.53$42,186-29.66%
2022-08-11Sale
15,000
0.0106%
$16.75$251,250-61.71%
2022-08-02SaleEVP of R&D and CMO
2,000
0.0013%
$11.97$23,940-47.84%
2022-07-05SaleEVP of R&D and CMO
2,000
0.0014%
$11.44$22,880-38.52%
2022-06-22Sale
10,000
0.0069%
$11.76$117,600-33.78%
2022-06-21SaleEVP of R&D and CMO
2,000
0.0014%
$11.18$22,360-30.17%
2022-05-19SaleEVP of R&D and CMO
11,500
0.0079%
$7.40$85,092+18.54%
2022-03-15SalePresident and CEO
23,648
0.0164%
$7.65$180,879+21.54%
2022-03-15SaleGeneral Counsel
8,849
0.0062%
$7.68$67,962+21.54%
2022-03-15SaleEVP of R&D and CMO
5,169
0.0036%
$7.71$39,848+21.54%

Insider Historical Profitability

<0.0001%
Belldegrun Ariedirector
1724137
0.8223%
$1.9040<0.0001%
Parker Geoffrey M.CHIEF FINANCIAL OFFICER
819590
0.3909%
$1.9010
Humer Franz Bdirector
307507
0.1467%
$1.9012+2.3%
MESSEMER DEBORAH M.director
157629
0.0752%
$1.9003
PFIZER INC10 percent owner
22032040
10.5079%
$1.9010+2.3%
TPG Group Holdings (SBS) Advisors, Inc.10 percent owner
18716306
8.9265%
$1.90117+2.3%
Chang David DPresident and CEO
2289652
1.092%
$1.9013+2.3%
Bhavnagri VeerGeneral Counsel
577677
0.2755%
$1.90016
Amado RafaelEVP of R&D and CMO
540257
0.2577%
$1.9009
Kazam Joshua Adirector
258885
0.1235%
$1.9010<0.0001%
WITTE OWEN N.
218271
0.1041%
$1.9015+2.3%
MOORE ALISONChief Technical Officer
120430
0.0574%
$1.90014
SCHMIDT ERIC THOMASChief Financial Officer
100546
0.048%
$1.9008
Mayo Stephendirector
25328
0.0121%
$1.9001

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$113.38M12.1725.36M+0.48%+$546,676.530.01
Tpg Gp A Llc$83.66M8.9818.72M0%+$01.62
BlackRock$43.15M4.639.65M-3.49%-$1.56M<0.01
State Street$41.05M4.419.18M+278.37%+$30.2M<0.01
The Vanguard Group$36.69M3.948.21M-9.12%-$3.68M<0.01
PRIMECAP Management Co$24.35M2.625.45M+3.15%+$744,254.990.02
JPMorgan Chase$23.16M2.495.18M-24.97%-$7.71M<0.01
T. Rowe Price$18.68M2.014.18M+76.16%+$8.07M<0.01
Boxer Capital, LLC$17.21M1.853.85MNew+$17.21M0.35
Citadel Advisors LLC$13.92M1.493.11M-23.19%-$4.2M0.01
Frazier Life Sciences Management L P$12.82M1.382.87MNew+$12.82M0.58
Woodline Partners LP$11.77M1.262.63M+2.19%+$252,447.730.1
Geode Capital Management$10.6M1.142.37M+1.55%+$161,570.86<0.01
Morgan Stanley$9.98M1.072.23M+33.83%+$2.52M<0.01
Dimensional Fund Advisors$9.13M0.982.04M+33.11%+$2.27M<0.01
Wildcat Capital Management$7.88M0.921.92M0%+$02.86
Two Sigma$8.54M0.921.91M-17.42%-$1.8M0.01
Vida Ventures Advisors Llc$8.04M0.861.8M0%+$04.47
Two Sigma Advisers LP$5.95M0.641.33M+4.18%+$238,698.000.01
Goldman Sachs$5.79M0.621.29M-61.21%-$9.13M<0.01
Rafferty Asset Management Llc$4.43M0.48990,703+332.61%+$3.4M0.01
Northern Trust$4.34M0.47971,067-4.27%-$193,452.64<0.01
Charles Schwab$3.84M0.41858,476+17.14%+$561,615.31<0.01
Nordea Investment Management Ab$3.38M0.36742,114+0.19%+$6,518.20<0.01
Octagon Capital Advisors LP$3.22M0.35720,000New+$3.22M0.02
Citigroup$3.03M0.33678,229+1,875.96%+$2.88M<0.01
UBS$2.32M0.25519,201+186.54%+$1.51M<0.01
Zacks Investment Management$2.06M0.22459,800+17.16%+$301,085.640.02
Td Asset Management Inc$1.96M0.21437,436+83.92%+$892,212.04<0.01
Caxton Associates$1.93M0.21431,186-44.37%-$1.54M0.09
Cerity Partners$1.9M0.2424,169-18.05%-$417,551.540.01
Coastal Bridge Advisors Llc$1.82M0.2406,8470%+$00.37
Bank of America$1.81M0.19404,382+22.21%+$328,518.26<0.0001
Renaissance Technologies$1.77M0.19396,900-13.46%-$275,991.31<0.01
Mirae Asset Global Investments Co Ltd$1.77M0.17361,913+85.14%+$812,904.26<0.01
Nuveen$1.35M0.15302,255-15.47%-$247,204.44<0.0001
BNY Mellon$1.34M0.14300,553-7.23%-$104,723.09<0.0001
Susquehanna Fundamental Investments Llc$1.28M0.14286,408New+$1.28M0.06
The Manufacturers Life Insurance Company$1.26M0.14282,150+37.48%+$343,814.66<0.01
Mitsubishi UFJ Kokusai Asset Management$972,203.000.1217,495-1.63%-$16,087.54<0.01
Swiss National Bank$960,156.000.1214,8000%+$0<0.01
Millennium Management LLC$900,571.000.1201,470-89.5%-$7.68M<0.01
Prudential Financial$886,901.000.1198,412-47.63%-$806,512.58<0.01
D. E. Shaw & Co.$875,127.000.09195,778+158.83%+$537,016.45<0.01
PDT Partners$844,955.000.09189,028+1,085.58%+$773,685.330.06
Ameriprise Financial$845,008.000.09189,040-0.66%-$5,609.85<0.0001
Ubs Asset Management Americas Inc$761,184.000.08170,287+8.66%+$60,693.75<0.0001
ExodusPoint Capital Management, LP$729,000.000.08163,023-64.78%-$1.34M0.01
Los Angeles Capital Management LLC$717,985.000.08160,623-3.23%-$23,936.86<0.01
Barclays$700,000.000.08156,747-15.23%-$125,756.79<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.